<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Blog Hub &#187; ENZN</title>
	<atom:link href="http://www.stockbloghub.com/tag/enzn/feed" rel="self" type="application/rss+xml" />
	<link>http://www.stockbloghub.com</link>
	<description>Start Your Investing Research Here!</description>
	<lastBuildDate>Wed, 23 May 2012 20:22:08 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>(ENZN) Enzon Pharmaceuticals Plans a 50% Workforce Cut</title>
		<link>http://www.stockbloghub.com/2011/09/27/enzn-enzon-pharmaceuticals-plans-a-50-workforce-cut/84114</link>
		<comments>http://www.stockbloghub.com/2011/09/27/enzn-enzon-pharmaceuticals-plans-a-50-workforce-cut/84114#comments</comments>
		<pubDate>Tue, 27 Sep 2011 20:45:43 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ENZN]]></category>
		<category><![CDATA[Enzon Pharmaceuticals Inc]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[Vertex Pharmaceuticals Incorporated]]></category>
		<category><![CDATA[VRTX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=84114</guid>
		<description><![CDATA[Enzon Pharmaceuticals (ENZN) recently announced that it will reduce its workforce by almost half to better align its resources with much tempered pipeline activities. The research and development pipeline at Enzon was reduced drastically in the last few months. During the second quarter, Enzon announced that it will no longer develop three messenger ribonucleic acid (mRNA) antagonists utilizing the LNA technology and returned the rights to Santaris. The mRNA antagonists, all of which were in phase I trials, were hypoxia-inducible factor-1 alpha (HIF-1 a) indicated for tumors and lymphoma, survivin indicated for cancer and pediatric patients with relapse acute lymphoblastic leukemia and androgen receptor (AR) for castration-resistant prostate cancer (CRPC). Earlier, in mid-May 2011, Enzon announced plans to halt the development of its lead pipeline candidate PEG-SN38 for the treatment ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/09/27/enzn-enzon-pharmaceuticals-plans-a-50-workforce-cut/84114/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ENZN) Enzon Pharmaceuticals Analyst Downgrades Shares to Sell</title>
		<link>http://www.stockbloghub.com/2011/09/15/enzn-enzon-pharmaceuticals-analyst-downgrades-shares-to-sell/83032</link>
		<comments>http://www.stockbloghub.com/2011/09/15/enzn-enzon-pharmaceuticals-analyst-downgrades-shares-to-sell/83032#comments</comments>
		<pubDate>Thu, 15 Sep 2011 17:49:51 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ENZN]]></category>
		<category><![CDATA[Enzon Pharmaceuticals Inc]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Vertex Pharmaceuticals Incorporated]]></category>
		<category><![CDATA[VRTX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=83032</guid>
		<description><![CDATA[We recently downgraded our rating on Enzon Pharmaceuticals Inc. (ENZN) from Neutral to Underperform with a target price of $9.50. In mid-May 2011, Enzon announced plans to halt the development of its lead pipeline compound PEG-SN38 (EZN-2208), a PEGylated version of the active metabolite of the cancer drug, irinotecan, for the treatment of metastatic colorectal cancer (mCRC). Enzon decided to halt development as the company intends to focus its resources on other areas with nearer-term commercial potential. The discontinuation of development of PEG-SN38 for mCRC is a disappointment, leaving the company with just one clinical program in mid-stage development (PEG-SN38 for metastatic breast cancer) and all others in early stages of development. The company’s pipeline candidates include PEG-SN38, hypoxia-inducible factor1 (HIF-1) alpha, survivin antagonists and multiple messenger RNA (mRNA) antagonists ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/09/15/enzn-enzon-pharmaceuticals-analyst-downgrades-shares-to-sell/83032/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ENZN) Enzon Pharmaceuticals&#8217; Weak Top Line Widens Loss</title>
		<link>http://www.stockbloghub.com/2011/08/09/enzn-enzon-pharmaceuticals-weak-top-line-widens-loss/80950</link>
		<comments>http://www.stockbloghub.com/2011/08/09/enzn-enzon-pharmaceuticals-weak-top-line-widens-loss/80950#comments</comments>
		<pubDate>Tue, 09 Aug 2011 19:23:45 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ENZN]]></category>
		<category><![CDATA[Enzon Pharmaceuticals Inc]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[Vertex Pharmaceuticals Incorporated]]></category>
		<category><![CDATA[VRTX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=80950</guid>
		<description><![CDATA[Enzon Pharmaceuticals’ (ENZN) second quarter 2011 net loss of 12 cents per share (excluding restructuring charge) was wider than the loss of 8 cents suffered in the year-ago quarter as the decline in royalty revenue neutralized the savings from cost-cutting initiatives. The Zacks Consensus Estimate indicated a break-even for the company. Total revenue at Enzon was $9.6 million, sharply down 30% year over year due to the decline in royalty revenue. Revenue was also much below the Zacks Consensus Estimate of $15 million. Royalty revenue in the quarter dropped around 13% to $9.2 million. Enzon earns the majority of its royalty revenue from the sale of PegIntron, marketed by Merck &#38; Co. (MRK), for treating patients suffering from hepatitis C virus (HCV). The decline in royalty revenue in the reported ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/08/09/enzn-enzon-pharmaceuticals-weak-top-line-widens-loss/80950/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ENZN) Enzon Pharmaceuticals &#8211; Bear of the Day</title>
		<link>http://www.stockbloghub.com/2011/06/15/enzn-enzon-pharmaceuticals-bear-of-the-day-2/76382</link>
		<comments>http://www.stockbloghub.com/2011/06/15/enzn-enzon-pharmaceuticals-bear-of-the-day-2/76382#comments</comments>
		<pubDate>Wed, 15 Jun 2011 13:52:44 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ENZN]]></category>
		<category><![CDATA[Enzon Pharmaceuticals Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=76382</guid>
		<description><![CDATA[Enzon Pharma&#8217;s (ENZN) first quarter 2011 net loss of $0.07 per share was narrower than the year-ago loss of $0.20 due to substantial cost cutting by management. The discontinuation of the development of PEG-SN38 for mCRC was a major blow to Enzon, leaving it with just one clinical program in mid-stage development and all other programs in early stages of development. Moreover, royalties from the sales of PegIntron, comprising a substantial part of revenues, have been declining. Recent FDA approval of Incivek and Victrelis can pose strong competition to PegIntron, which could further decline royalties from PegIntron sales. We have, therefore, downgraded our rating on the stock from Neutral to Underperform. At the end of the first quarter, P/B multiple of the stock was approximately 2.1. Our price target of ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/15/enzn-enzon-pharmaceuticals-bear-of-the-day-2/76382/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ENZN) Enzon Pharmaceuticals &#8211; Bear of the Day</title>
		<link>http://www.stockbloghub.com/2011/06/07/enzn-enzon-pharmaceuticals-bear-of-the-day/75664</link>
		<comments>http://www.stockbloghub.com/2011/06/07/enzn-enzon-pharmaceuticals-bear-of-the-day/75664#comments</comments>
		<pubDate>Tue, 07 Jun 2011 14:49:09 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ENZN]]></category>
		<category><![CDATA[Enzon Pharmaceuticals Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=75664</guid>
		<description><![CDATA[Enzon Pharma&#8217;s (ENZN) first quarter 2011 net loss of $0.07 per share was narrower than the year-ago loss of $0.20 due to substantial cost cutting by management. The discontinuation of the development of PEG-SN38 for mCRC was a major blow to Enzon, leaving it with just one clinical program in mid-stage development and all other programs in early stages of development. Moreover, royalties from the sales of PegIntron, comprising a substantial part of revenues, have been declining. Recent FDA approval of Incivek and Victrelis can pose strong competition to PegIntron, which could further decline royalties from PegIntron sales. We have, therefore, downgraded our rating on the stock from Neutral to Underperform. At the end of the first quarter, P/B multiple of the stock was approximately 2.1. Our price target of ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/07/enzn-enzon-pharmaceuticals-bear-of-the-day/75664/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(SONS) ValuEngine Weekly News</title>
		<link>http://www.stockbloghub.com/2011/04/25/sons-valuengine-weekly-news/72173</link>
		<comments>http://www.stockbloghub.com/2011/04/25/sons-valuengine-weekly-news/72173#comments</comments>
		<pubDate>Mon, 25 Apr 2011 15:59:18 +0000</pubDate>
		<dc:creator>valuengine</dc:creator>
				<category><![CDATA[Communication Equipment]]></category>
		<category><![CDATA[Technology]]></category>
		<category><![CDATA[Alliant Techsystems Inc.]]></category>
		<category><![CDATA[American Superconductor Corporation]]></category>
		<category><![CDATA[AMR]]></category>
		<category><![CDATA[AMR Corporation]]></category>
		<category><![CDATA[AMSC]]></category>
		<category><![CDATA[ATK]]></category>
		<category><![CDATA[Cemex S.A.B. de C.V.]]></category>
		<category><![CDATA[Cheniere Energy Inc]]></category>
		<category><![CDATA[COMV]]></category>
		<category><![CDATA[Comverge Inc]]></category>
		<category><![CDATA[COOL]]></category>
		<category><![CDATA[CX]]></category>
		<category><![CDATA[EarthLink Inc.]]></category>
		<category><![CDATA[EchoStar Corporation]]></category>
		<category><![CDATA[ELNK]]></category>
		<category><![CDATA[ENZN]]></category>
		<category><![CDATA[Enzon Pharmaceuticals Inc]]></category>
		<category><![CDATA[FDML]]></category>
		<category><![CDATA[Federal-Mogul Corporation]]></category>
		<category><![CDATA[GSI Commerce Inc]]></category>
		<category><![CDATA[GSIC]]></category>
		<category><![CDATA[H]]></category>
		<category><![CDATA[Hyatt Hotels Corporation]]></category>
		<category><![CDATA[Imation Corporation]]></category>
		<category><![CDATA[IMN]]></category>
		<category><![CDATA[Jabil Circuit Inc.]]></category>
		<category><![CDATA[JBL]]></category>
		<category><![CDATA[KLA-Tencor Corporation]]></category>
		<category><![CDATA[KLAC]]></category>
		<category><![CDATA[Lam Research Corporation]]></category>
		<category><![CDATA[Leucadia National Corporation]]></category>
		<category><![CDATA[LNG]]></category>
		<category><![CDATA[LRCX]]></category>
		<category><![CDATA[LUK]]></category>
		<category><![CDATA[Majesco Entertainment Company]]></category>
		<category><![CDATA[Manitowoc Company Inc]]></category>
		<category><![CDATA[MERC]]></category>
		<category><![CDATA[Mercer International Inc.]]></category>
		<category><![CDATA[Mindspeed Technologies Inc.]]></category>
		<category><![CDATA[MSPD]]></category>
		<category><![CDATA[MTW]]></category>
		<category><![CDATA[Online Resources Corporation]]></category>
		<category><![CDATA[ORCC]]></category>
		<category><![CDATA[Portugal Telecom SGPS SA]]></category>
		<category><![CDATA[Power-One Inc.]]></category>
		<category><![CDATA[PT]]></category>
		<category><![CDATA[PWER]]></category>
		<category><![CDATA[Radian Group Inc.]]></category>
		<category><![CDATA[RDN]]></category>
		<category><![CDATA[REV]]></category>
		<category><![CDATA[Revlon Inc.]]></category>
		<category><![CDATA[SATS]]></category>
		<category><![CDATA[SIGM]]></category>
		<category><![CDATA[Sigma Designs Inc.]]></category>
		<category><![CDATA[SONS]]></category>
		<category><![CDATA[Sonus Networks Inc]]></category>
		<category><![CDATA[STM]]></category>
		<category><![CDATA[STMicroelectronics NV]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=72173</guid>
		<description><![CDATA[MARKET OVERVIEW Index started week Thursday Close 4 day change 4 day change % ytd DJIA 12339.71 12506 166.29 1.35% 8.02% NASDAQ 2731.22 2820.16 88.94 3.26% 6.31% RUSSELL 2000 826.99 845.64 18.65 2.26% 7.91% S&#38;P 500 1313.35 1337.38 24.03 1.83% 6.34% SECTOR OVERVIEW Sector Change MTD YTD Valuation Last 12-MReturn P/E Ratio Aerospace 0.42% -1.69% 13.98% 8.03% overvalued 16.03% 19.22 Auto-Tires-Trucks 1.68% -0.21% -2.61% 7.37% overvalued 29.12% 20.38 Basic Materials 0.74% -0.03% 1.00% 10.49% overvalued 46.56% 25.93 Business Services 0.46% 0.30% 6.06% 8.89% overvalued 9.60% 50.9 Computer and Technology 0.52% 0.43% 12.52% 8.67% overvalued 24.94% 45.93 Construction 0.18% -1.44% 1.00% 5.60% overvalued -0.55% 34.25 Consumer Discretionary 0.56% 1.73% 7.36% 5.60% overvalued 10.04% 33.27 Consumer Staples 0.30% -0.16% -0.60% 9.70% overvalued 12.48% 19.29 Finance 0.47% -0.91% 2.53% 6.83% overvalued 3.25% 25.94 ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/04/25/sons-valuengine-weekly-news/72173/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ENZN) Enzon Pharmaceuticals Analyst Holds Shares at Neutral</title>
		<link>http://www.stockbloghub.com/2011/04/09/enzn-enzon-pharmaceuticals-analyst-holds-shares-at-neutral/70655</link>
		<comments>http://www.stockbloghub.com/2011/04/09/enzn-enzon-pharmaceuticals-analyst-holds-shares-at-neutral/70655#comments</comments>
		<pubDate>Sat, 09 Apr 2011 19:27:34 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ENZN]]></category>
		<category><![CDATA[Enzon Pharmaceuticals Inc]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Vertex Pharmaceuticals Incorporated]]></category>
		<category><![CDATA[VRTX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=70655</guid>
		<description><![CDATA[We have maintained our Neutral recommendation on Enzon Pharmaceuticals, Inc. (ENZN) with a target price of $12.00 after announcement of fourth quarter and full year 2010 results. Enzon Pharmaceuticals’ fourth quarter 2010 net loss of 14 cents per share (excluding special items) was wider than the Zacks Consensus Estimate, which indicated a loss of 8 cents. The loss, however, compared favorably with a loss of 21 cents suffered in the year-ago quarter.  On a reported basis (including special items), the company saw a loss from continuing operations of 17 cents as against a loss of 32 cents per share in the year-ago quarter. The narrower loss in the quarter emanated from the divestiture of the specialty pharmaceutical business (January 2010) and subsequent cost savings at Enzon. The debt burden at ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/04/09/enzn-enzon-pharmaceuticals-analyst-holds-shares-at-neutral/70655/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ENZN) Enzon Pharmaceuticals Analyst Cuts Shares to Underperform</title>
		<link>http://www.stockbloghub.com/2010/11/17/enzn-enzon-pharmaceuticals-analyst-cuts-shares-to-underperform/59437</link>
		<comments>http://www.stockbloghub.com/2010/11/17/enzn-enzon-pharmaceuticals-analyst-cuts-shares-to-underperform/59437#comments</comments>
		<pubDate>Thu, 18 Nov 2010 05:18:08 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ENZN]]></category>
		<category><![CDATA[Enzon Pharmaceuticals Inc]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=59437</guid>
		<description><![CDATA[We are downgrading Enzon Pharmaceuticals (ENZN) to Underperform from Neutral because of concerns regarding the disappointing third quarter results, declining royalty revenues, the principal source of revenues at Enzon and the early stage pipeline. Based in Bridgewater, New Jersey, Enzon is a biopharmaceutical company dedicated to the discovery, development, and commercialization of therapeutics to treat cancer and other life-threatening diseases. There are a number of reasons for the negative sentiment regarding Enzon. Following the sale of the specialty pharmaceutical business earlier in the year, Enzon has no marketed product and its revenues consist primarily of royalties.  For example, approximately 82% of third quarter 2010 revenues came from royalties. However, royalty revenues, the majority of which comes from the sale of Merck &#38; Co. Inc.’s (MRK) PegIntron, declined 16% in the ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/11/17/enzn-enzon-pharmaceuticals-analyst-cuts-shares-to-underperform/59437/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ENZN) Enzon Beats Expectations &#8211; Announces Sell-off</title>
		<link>http://www.stockbloghub.com/2009/11/11/enzn-enzon-beats-expectations-announces-sell-off/20250</link>
		<comments>http://www.stockbloghub.com/2009/11/11/enzn-enzon-beats-expectations-announces-sell-off/20250#comments</comments>
		<pubDate>Wed, 11 Nov 2009 20:42:34 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ENZN]]></category>
		<category><![CDATA[Enzon Pharmaceuticals Inc]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[OSI Pharmaceuticals Inc]]></category>
		<category><![CDATA[OSIP]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=20250</guid>
		<description><![CDATA[Enzon (ENZN) achieved break-even earnings during the third quarter of 2009, better than the Zacks Consensus Estimate of loss of 7 cents but below the year-ago earnings of 1 cent. The company reported revenues of $44.6 million, a decline of 9% compared to $48.8 million reported in the third quarter of 2008. Enzon records revenues from three sources &#8212; products, royalties and contract manufacturing. The three segments recorded a decline of 1%, 6% and 56%, respectively, compared to the year-ago period. Enzon has four marketed products &#8212; Oncaspar for the treatment of acute lymphoblastic leukemia (ALL); DepoCyt for lymphomatous meningitis; Abelcet for antifungal infection related to cancer and Adagen used to treat severe combined immunodeficiency disease (SCID), commonly known as the &#8220;bubble boy&#8221; disease. Apart from Oncaspar, whose sales remained ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/11/11/enzn-enzon-beats-expectations-announces-sell-off/20250/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ENZN) Enzon Pharma Announces European Approval for Cimzia</title>
		<link>http://www.stockbloghub.com/2009/10/08/enzn-enzon-pharma-announces-european-approval-for-cimzia/17197</link>
		<comments>http://www.stockbloghub.com/2009/10/08/enzn-enzon-pharma-announces-european-approval-for-cimzia/17197#comments</comments>
		<pubDate>Thu, 08 Oct 2009 19:10:06 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ENZN]]></category>
		<category><![CDATA[Enzon Pharmaceuticals Inc]]></category>
		<category><![CDATA[OSI Pharmaceuticals Inc]]></category>
		<category><![CDATA[OSIP]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Schering-Plough Corporation]]></category>
		<category><![CDATA[SGP]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=17197</guid>
		<description><![CDATA[Yesterday, Enzon Pharma (ENZN) announced the European Commission approval of UCB’s Cimzia (certolizumab pegol) for the treatment of adult patients with moderate-to-severe active rheumatoid arthritis (RA). Cimzia utilizes Enzon&#8217;s PEGylation technology. Earlier in May 2009, Cimzia received the US Food and Drug Administration&#8217;s (FDA) approval. Apart from RA, the drug is used to treat Crohn’s disease. Cimzia is a PEGylated anti-TNFa &#8211; Tumor Necrosis Factor alpha. Enzon receives royalties from several drugs manufactured using this technology – Schering Plough’s (SGP) Pegintron, Macugen marketed by Pfizer (PFE) and OSI Pharmaceuticals (OSIP) and Roche’s Pegasys. We believe the approval of Cimzia will boost its sales, thereby increasing the royalty income for Enzon. In a positive development, earlier this week, an FDA advisory panel voted in favor of recommending Pegintron as a treatment in ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/10/08/enzn-enzon-pharma-announces-european-approval-for-cimzia/17197/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BMRN) BioMarin Pharmaceutical Begins Mid-Stage Trial</title>
		<link>http://www.stockbloghub.com/2009/09/23/bmrn-biomarin-pharmaceutical-begins-mid-stage-trial/15916</link>
		<comments>http://www.stockbloghub.com/2009/09/23/bmrn-biomarin-pharmaceutical-begins-mid-stage-trial/15916#comments</comments>
		<pubDate>Wed, 23 Sep 2009 19:42:18 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ALTU]]></category>
		<category><![CDATA[Altus Pharmaceuticals Inc]]></category>
		<category><![CDATA[Biomarin Pharmaceutical Inc]]></category>
		<category><![CDATA[BMRN]]></category>
		<category><![CDATA[ENZN]]></category>
		<category><![CDATA[Enzon Pharmaceuticals Inc]]></category>
		<category><![CDATA[Merck & Company Inc.]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[Shire Limited]]></category>
		<category><![CDATA[SHPGY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=15916</guid>
		<description><![CDATA[Yesterday, BioMarin Pharmaceutical Inc. (BMRN) said it started a mid-stage study of PEG-PAL for the treatment of phenylketonuria (PKU). The company expects initial results from the study in mid-2010. It is co-developing the candidate with Merck Serono (MRK). The primary objective of the open-label, multi-center study, to be conducted in up to 35 patients, is to evaluate the effect of PEG-PAL on blood phenylalanine (Phe) concentrations in PKU patients. The secondary objectives are to evaluate its safety and tolerability, immune response and steady state pharmacokinetics of subcutaneous injections of multiple dose levels. BioMarin, which competes with companies such as Enzon Pharmaceuticals Inc. (ENZN), Shire Plc (SHPGY) and Altus Pharmaceuticals Inc. (ALTU), already has Kuvan in the market for treating PKU. The primary difference between PEG-PAL and Kuvan is the mode ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/09/23/bmrn-biomarin-pharmaceutical-begins-mid-stage-trial/15916/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

